THE FUTURE, - Solvay

New
business
22
New business > INNOVATIONS 09
209807 209809 209810
ONE DIE AND ONE LINE TO PRODUCE A WIDE
VARIETY OF PVC HONEYCOMB
More fl exible
and recyclable
THE PROJECT. The production process of
Nidacell ® PVC honeycomb structures has
undergone a series of innovations to better meet
the demands of a market looking for fl exible
solutions to reduce the weight and cost of fi nished
products. It is also allowing us to differentiate
ourselves from competitor honeycombs in terms
of both geometric structure and production
method.
Fed with PVC powder or granules, the Nidacell ®
line offers the possibility of producing rigid,
fl exible or supple honeycombs and multilayer
honeycombs with a fi lm of heat reactive adhesive
deposited on top of the cell walls by the simple
use of a commercial coextrusion block.
Furthermore, the Nidacell ® process allows
manufacturers to develop – for a limited
investment – a whole range of honeycombs
of different thicknesses, rigidities and fl exibilities
and to market products of all types, sizes and
geometric shapes. Finally, the introduction of a
laser welding technology to create the panels
eliminates the use of an adhesive layer to
assemble the various components, allowing for a
complete recycling of the whole, including
production waste.
The launch of a fi rst production line implementing
the Nidacell ® process under licence is scheduled
to take place in September 2009.
CC MATERIALS
DEVELOPMENT AND ANALYSIS
> Claude Dehennau; Claudine Bloyaert;
Philippe Cerclier; Philippe Devesvre; Joel Fumire;
Dominique Grandjean; François Groussard;
Philippe-Jacques Leng; Matthieu Meurat;
Jean Schoemans; Philippe Vallot.
SOLVAY TEAMS WITH PETROVAX:
PIONEERING BOOST TO INFLUENZA
VACCINES MARKET WITH NEW INNOVATIVE
PRODUCTS
Storming the Russian
market…
THE PROJECT. How to increase Solvay
Pharma Russia’s share of the infl uenza vaccine
market? Our aim was to enter the National
Vaccination Calendar and to increase our global
infl uenza vaccine expertise by expanding our
portfolio. We adopted a creative plan: combining
Solvay’s skills and technologies with those of
Russian Petrovax to produce two novel,
next-generation vaccines for the Russian and CIS
markets. The fi rst Grippol Plus ® was approved in
Russia in September 2008. Partnering with
Petrovax, we strengthen and expand our portfolio
in Russia (and ultimately on the global
marketplace) with new generation infl uenza
vaccines and other immuno-biological products
which can be produced locally in a new facility.
PHARMACEUTICALS SECTOR
> Leonid Parshenkov; Sjirk Kok; Arkady Nekrasov;
Natalia Puchkova.
INNOGENETICS PIONEER DIAGNOSTICS:
EARLY ACCURATE DIAGNOSIS OF
ALZHEIMER’S DISEASE
Innogenetics:
a promising market
THE PROJECT. Dementia, including
Alzheimer’s disease (AD), represents a serious
and rapidly growing challenge for society. It is
increasingly important to diagnose it early,
with the use of biomarkers being key in the
development of effective future AD treatments.
Innogenetics is a key player in early and accurate
AD diagnosis, with its AlzBio3 test selected by
ADNI (Alzheimer Neuro-Imaging Initiative) in the
USA for exclusive use in its testing protocols
following rigorous validation studies in the US
and Europe. Innogenetics is uniquely placed to
have the fi rst FDA approved diagnostic assays for
AD, initially using cerebrospinal fl uid but later
moving to the more easily accessed blood plasma.
PHARMACEUTICALS SECTOR
> Sander Vanhulsenbeek; Dirk Lepoudre;
Eddy Tordeur.